Comprehensive Management of Hypertension, Dyslipidemia, and Type 2 Diabetes

Initial Management Approach

The American Diabetes Association and European Heart Society recommend a combination of lifestyle modifications and pharmacological therapy targeting all three conditions, with ACE inhibitors or ARBs as first-line antihypertensive therapy, statins for dyslipidemia, and appropriate glucose control for a patient with hypertension, dyslipidemia, and type 2 diabetes 1, 2

The American Heart Association recommends implementing weight loss if overweight through caloric restriction and increased physical activity for patients with hypertension, dyslipidemia, and type 2 diabetes 1, 2
Adopting a DASH or Mediterranean-style eating pattern is recommended by the American Diabetes Association for patients with hypertension, dyslipidemia, and type 2 diabetes 1, 2
Increasing consumption of fruits, vegetables, and low-fat dairy products is recommended by the American Heart Association for patients with hypertension, dyslipidemia, and type 2 diabetes 1, 2
Engaging in moderate-to-vigorous physical activity for ≥150 minutes per week, combining aerobic and resistance exercise, is recommended by the European Heart Society for patients with hypertension, dyslipidemia, and type 2 diabetes 2

The American Heart Association recommends targeting a blood pressure goal of <130/80 mmHg for patients with hypertension, dyslipidemia, and type 2 diabetes 1, 2
First-line antihypertensive therapy should include an ACE inhibitor or ARB, particularly given the presence of diabetes, as recommended by the European Heart Society 2
Consider combination with a thiazide-like diuretic or dihydropyridine calcium channel blocker, as recommended by the American Diabetes Association 1, 2

The European Heart Society recommends initiating statin therapy as first-line treatment for dyslipidemia in patients with type 2 diabetes 2
Targeting LDL-C <1.4 mmol/L (<55 mg/dL) and reduction of at least 50% is recommended by the European Heart Society for patients with type 2 diabetes at very high cardiovascular risk 2
If target LDL-C is not reached with maximum tolerated statin dose, consider adding ezetimibe, as recommended by the European Heart Society 2

The European Heart Society recommends targeting HbA1c <7.0% (individualized based on patient characteristics) for patients with type 2 diabetes 2, 5
Consider SGLT2 inhibitors or GLP-1 receptor agonists due to their cardiovascular benefits, as recommended by the European Heart Society 2
Avoid hypoglycemia, as recommended by the European Heart Society 2

Obtain a lipid profile at initiation of statin therapy and periodically thereafter, as recommended by the American Diabetes Association 1
Monitor blood pressure regularly to ensure target achievement, as recommended by the American Diabetes Association 6
Assess adherence to medications and lifestyle modifications at each visit, as recommended by the American College of Physicians 7